Biotech Is 'Very Bullish'

Folks, a major change is taking place in the world of biotechnology... We're entering an era of personalized medicine. That's where a doctor can order a genetic work-up and prescribe treatment based on the very genetic [Chaikin PowerFeed]( Biotech Is 'Very Bullish' By Vic Lederman, editorial director, Chaikin Analytics Folks, a major change is taking place in the world of biotechnology... We're entering an era of personalized medicine. That's where a doctor can order a genetic work-up and prescribe treatment based on the very genetic markers that make you an individual. Beyond that, artificial intelligence ("AI") is helping in the world of drug development. And it's only getting better. Specifically, I'm talking about the fact that AI tools can "brainstorm" millions of new possible drugs. And they can do it faster than any human can. Just those two things together mean we're on the edge of a revolution in modern medicine. But there's something else that you've probably heard about... A new class of weight-loss drugs are on the market. And it seems like just about everyone is talking about them. The industry calls them glucagon-like peptide 1 (GLP-1) agonists. But you've probably heard about the brand names – Ozempic, Wegovy, and Mounjaro. They have become wildly popular. Folks, it's looking like humanity may have legitimately cracked the code on weight loss. These new drugs literally change the way you think and feel about food. And with all this change taking place, it's no surprise the Power Gauge has picked up on the strength in biotech... Recommended Links: [Stansberry Research Employee: 'This Technology Saved My Life']( An employee at our corporate affiliate Stansberry Research – not an analyst or anyone you've met before – is taking the "mic" to tell everything. His story is unlike anything you've ever seen. And it holds the secret to a generational opportunity you won't be able to ignore after you've seen it. Warning: [This is extremely personal](. [Warren Buffett's Next Big Winner?]( He made 2,307% on Coca-Cola, 2,266% on GEICO, and even 3,200% on Moody's. Yet this next Buffett pick could be even higher. It's NOT artificial intelligence... cryptocurrency... or anything like that. In fact, what it is may shock you. [Find out what it is](. You don't have to be a biotech expert to notice that something big is going on. That's the magic of the Power Gauge. You see, the Power Gauge rates individual stocks using 20 of the most important factors on Wall Street. And together, those factors go through a proprietary weighting system. The final output is a simple rating – from "very bullish" to "very bearish" – for any stock. But when it comes to entire sectors and subsectors, we can use the Power Gauge to get a bird's-eye view. With biotech, we can track it with the SPDR S&P Biotech Fund (XBI). It's an exchange-traded fund ("ETF") with holdings across the biotech subsector. Take a look at this screenshot from the Power Gauge... [Chaikin PowerFeed] This shows XBI's Power Bar rating. The Power Bar allows us to quickly see the rating breakdown for every rated stock in an ETF. In the case of XBI, that's the proprietary weighting of the 20-factor Power Gauge report for 119 holdings with ratings in our system. Now, our testing shows that ratio between the bullish and bearish stocks is key. And as the Power Gauge shows, biotech stocks are considerably more "bullish" than they are "bearish." Specifically, XBI holds 37 stocks with a "bullish" or "very bullish" rating. And only 11 of its stocks earn a "bearish" or "very bearish" rating. Combining that with the fund's recent uptrend – up about 24% over the past six months – means a "very bullish" overall rating on XBI itself. In other words, biotech is "very bullish" right now. Now, in the world of medicine it always feels like there's some new "gee whiz" claim. And I'm sure you've felt like one day scientists are telling you something like chocolate is good for you... and the next day they say it's bad. Don't let that distract you from the real changes that are taking place. We're in the early stages of a medical and biotech revolution. The Power Gauge sees it through the individual ratings of biotech stocks. And when bringing them together, like in an ETF such as XBI, we see that the entire subsector is "very bullish." So if you're not watching biotech already, I recommend you look into it. Good investing, Vic Lederman P.S. In fact, our friends over at our corporate affiliate Stansberry Research just shared an emotional story from one of their own employees about the incredible power of biotech. It's the most personal – and eye-opening – message that Stansberry has ever shared. And as the folks there say, this message is also at the center of one of the biggest investing stories of the next decade or more. [Check it out right here](. Market View Major Indexes and Notable Sectors # Hld: Bullish Neutral Bearish Dow 30 +0.11% 15 15 0 S&P 500 -0.16% 193 256 48 Nasdaq -0.77% 41 49 10 Small Caps +0.41% 496 1037 378 Bonds -0.48% Energy +1.6% 2 17 4 — According to the Chaikin Power Bar, Large Cap stocks remain somewhat more Bullish than Small Cap stocks. Major indexes are all strongly bullish. * * * * Sector Tracker Sector movement over the last 5 days Energy +3.72% Materials +2.77% Communication +2.35% Financial +1.35% Utilities +1.11% Staples +1.09% Industrials +0.78% Discretionary +0.77% Information Technology +0.74% Health Care +0.3% Real Estate -0.2% * * * * Industry Focus Oil & Gas Exploration & Production Services 6 40 8 Over the past 6 months, the Oil & Gas Exploration & Production subsector (XOP) has underperformed the S&P 500 by -18.93%. Its Power Bar ratio, which measures future potential, is Weak, with more Bearish than Bullish stocks. It is currently ranked #16 of 21 subsectors and has moved up 4 slots over the past week. Indicative Stocks [rating] CLNE Clean Energy Fuels C [rating] TALO Talos Energy Inc. [rating] WTI W&T Offshore, Inc. * * * * Top Movers Gainers [rating] FCX +7.56% [rating] MMM +5.42% [rating] VLO +5.24% [rating] MPC +4.24% [rating] NEE +4.18% Losers [rating] DLTR -14.21% [rating] FICO -6.23% [rating] TSLA -4.54% [rating] INTC -4.44% [rating] GL -4.24% * * * * Earnings Report Reporting Today Rating Before Open After Close SCHW DG ADBE, ULTA No earnings reporting today. Earnings Surprises [rating] LEN Lennar Corporation Q1 $2.61 Beat by $0.39 [rating] WSM Williams-Sonoma, Inc. Q4 $5.44 Beat by $0.28 [rating] DLTR Dollar Tree, Inc. Q4 $2.55 Missed by $-0.10 * * * * You have received this e-mail as part of your subscription to PowerFeed. If you no longer want to receive e-mails from PowerFeed, [click here](. You’re receiving this e-mail at {EMAIL}. For questions about your account or to speak with customer service, call [+1 (877) 697-6783 (U.S.)](tel:18776976783), 9 a.m. - 5 p.m. Eastern time or e-mail info@chaikinanalytics.com. Please note: The law prohibits us from giving personalized investment advice. © 2024 Chaikin Analytics, LLC. All rights reserved. Any reproduction, copying, or redistribution, in whole or in part, is prohibited without written permission from Chaikin Analytics, LLC. 201 King Of Prussia Rd., Suite 650, Radnor, PA 19087. [www.chaikinanalytics.com.]( Any brokers mentioned constitute a partial list of available brokers and is for your information only. Chaikin Analytics, LLC, does not recommend or endorse any brokers, dealers, or investment advisors. Chaikin Analytics forbids its writers from having a financial interest in any security they recommend to our subscribers. All employees of Chaikin Analytics, LLC (and affiliated companies) must wait 24 hours after an investment recommendation is published online – or 72 hours after a direct mail publication is sent – before acting on that recommendation. This work is based on SEC filings, current events, interviews, corporate press releases, and what we've learned as financial journalists. It may contain errors, and you shouldn't make any investment decision based solely on what you read here. It's your money and your responsibility.